Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SIR9900
- Development stage
- Phase 2
- Lead developer
- Sironax
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
SIR9900 is a potent, selective, and CNS-penetrable small molecule inhibitor of receptor-interacting serine/threonine kinase 1 (RIPK1), developed by Sironax Ltd. It is designed to treat a range of neurodegenerative, autoimmune, and inflammatory conditions by modulating RIPK1-mediated necroptosis and inflammatory signaling. The drug has demonstrated high blood-brain barrier permeability, with a cerebrospinal fluid to unbound plasma ratio of 1.15, making it a candidate for central nervous system disorders such as Alzheimer's disease, multiple sclerosis, and amyotrophic lateral sclerosis (ALS). In Phase 1 clinical trials, SIR9900 showed favorable safety and tolerability, achieving approximately 90% peripheral target engagement and sustained RIPK1 inhibition.
02
Targets
RIPK1 (Receptor-interacting serine/threonine-protein kinase 1)
Beyond the preview
Go deeper on SIR9900.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SIR9900.